Harrow (HROW) Q4 2025 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Tue, March 3, 2026 astatine 10:01 AM CST 63 min read

Image source: The Motley Fool.

Tuesday, March 3, 2026 astatine 8 a.m. ET

• Chief Executive Officer — Mark L. Baum

• President and Chief Financial Officer — Andrew R. Boll

• Chief Commercial Officer — Patrick Sullivan

• Chief Scientific Officer — Amir Shojaei

• Vice President of Investor Relations and Communications — Michael Biega

Need a punctuation from a Motley Fool analyst? Email [email protected]

Michael Biega: Good morning. Welcome to Harrow Health, Inc.'s 4th fourth and afloat twelvemonth 2025 net league call. My sanction is Michael Biega, Vice President of Investor Relations and Communications, and I americium excited to beryllium introducing today's call. The company's remarks whitethorn see forward-looking statements wrong the meaning of national securities laws. Forward-looking statements are taxable to galore risks and uncertainties, galore of which are beyond Harrow Health, Inc.'s control, including risks and uncertainties described from clip to clip successful its SEC filings, specified arsenic the risks and uncertainties related to the company's quality to marque commercially disposable its FDA-approved products and compounded formulations and technologies and FDA support of definite cause candidates successful a timely mode oregon astatine all.

For a database and statement of those risks and uncertainties, delight spot the Risk Factors conception of the company's astir caller yearly study connected Form 10-K filed with the Securities and Exchange Commission. Harrow Health, Inc.'s results whitethorn disagree materially from those projected. Harrow Health, Inc. disclaims immoderate volition oregon work to update oregon revise immoderate fiscal projections oregon forward-looking statements, whether due to the fact that of caller information, aboriginal events, oregon otherwise. This league telephone contains time-sensitive accusation and is close lone arsenic of today. Joining maine connected today's telephone are Mark L. Baum, Chief Executive Officer, Andrew R. Boll, President and Chief Financial Officer, Patrick Sullivan, Chief Commercial Officer, and Amir Shojaei, Chief Scientific Officer.

With that, I would similar to crook the telephone implicit to Mark. Mark.

Mark L. Baum: Good morning. Thank you for joining us. Over the past 5 years, Harrow Health, Inc. has undergone a cardinal transformation. Harrow Health, Inc. present owns 1 of the largest portfolios of medicine ophthalmic products successful the United States market. We person been the astir prolific acquirer of ophthalmic pharmaceutical products successful the U.S. market, having completed much than a fractional a twelve transactions, integrating implicit 15 branded products into our scalable commercialized level that reaches each populated region wrong the United States and touches with interaction astir each cardinal ophthalmic illness segment.